<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121593</article-id><article-id pub-id-type="doi">10.23868/gc121593</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Stem cells in carcinogenesis of glioblastoma multiforme</article-title><trans-title-group xml:lang="ru"><trans-title>Стволовые клетки в канцерогенезе мультиформной глиобластомы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bryukhovetskyi</surname><given-names>IS. S</given-names></name><name xml:lang="ru"><surname>Брюховецкий</surname><given-names>И. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bryukhovetskyia</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Брюховецкий</surname><given-names>А. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kumeiko</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Кумейко</surname><given-names>В. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mischenko</surname><given-names>P. V</given-names></name><name xml:lang="ru"><surname>Мищенко</surname><given-names>П. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khotimchenko</surname><given-names>Y. S</given-names></name><name xml:lang="ru"><surname>Хотимченко</surname><given-names>Ю. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.V. Zhirmunsky Institute of Marine Biology of the FEB RAS, Vladivostok</institution></aff><aff><institution xml:lang="ru">Институт биологии моря им. А.В. Жирмунского ДВО РАН, Владивосток</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Research Centre of Specialized Types of Medical Care and Technologies of the FMBA of Russia, Moscow</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России, Москва</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Far Eastern Federal University, Vladivostok</institution></aff><aff><institution xml:lang="ru">Дальневосточный федеральный университет, Владивосток</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><issue-title xml:lang="en">VOL 8, NO2 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 8, №2 (2013)</issue-title><fpage>13</fpage><lpage>19</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Эко-Вектор</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121593">https://genescells.ru/2313-1829/article/view/121593</self-uri><abstract xml:lang="en"><p>Glioblastoma multiforme is a malignant primary brain tumor with a very poor prognosis. Neural stem and progenitor cells of the adult brain, as well as other types of stem cells are considered by carcinogenesis researchers the most likely source of malignant gliomas. This is evidenced by common genes regulating key processes of life, uniform proteomic profiles and identical immunophenotypical cell surface markers. These cells are highly proliferative, multipotent, able to independently migrate to the damaged area and have extensive replicative potential. However, antitumor properties of the stem cells (SCs) are also confirmed. The bodies of adult mammals and humans have genetically fixed mechanisms of control over their populations and multiple levels of antitumor protection. So far, the role of autologous SCs in a tumor patient is not clear. On the one hand, they fail to fulfill their anti-tumor and regulatory functions, and instead of organizing anti-tumor response become one of the key elements of carcinogenesis contributing to the development of neoplastic tumor vascular network and modulating the processes of neurogenesis, which is the main source of its pathological reinnervation, and therefore, a pain. On the other hand, autologous stem cells trigger powerful proliferative processes in the tumor tissue becoming the driving force of neoplastic growth. Apparently, due to the interaction of tumor cells with autologous stem cells, general and local interstitial patterns of autoregulation and sanogenesis are disturbed making tumor growth possible in principle. From this perspective, the technology that directly affects the population of cancer stem cells seems the most promising.</p></abstract><trans-abstract xml:lang="ru"><p>Мультиформная глиобластома — первичная злокачественная опухоль мозга с крайне неблагоприятным прогнозом. Нейральные стволовые и прогениторные клетки взрослого мозга, как и другие типы стволовых клеток, рассматриваются исследователями канцерогенеза как наиболее вероятный источник происхождения злокачественных глиом. Об этом свидетельствуют общность генов, регулирующих ключевые жизненные процессы, сходство проте-омного профиля и единство иммунофенотипических кластеров дифференцировки. Эти клетки обладают высокой пролиферативной активностью, мультипотентны, способны самостоятельно мигрировать в область повреждения, имеют большой репликативный потенциал. Однако доказаны и противоопухолевые свойства стволовых клеток. Организм взрослых млекопитающих и человека располагает генетически закрепленными механизмами контроля над их популяцией и многоуровневой системой противоопухолевой защиты. Но роль собственных стволовых клеток в организме пациента с опухолью неоднозначна. С одной стороны, они перестают выполнять свои регуляторные функции, вместо организации противоопухолевого ответа становясь одним из важнейших звеньев канцерогенеза, способствуя развитию неопластической кровеносной сети опухоли и модулируя процессы нейрогенеза — главного источника её патологической реиннервации, и соответственно, боли. С другой стороны, собственные стволовые клетки запускают мощные пролиферативные процессы в опухолевой ткани, становясь движущей силой неопластического роста. По-видимому, благодаря взаимодействию опухолевых клеток с собственными стволовыми клетками нарушаются общие и местные внутритканевые закономерности ауторегуляции и саногенеза, что делает опухолевый рост принципиально возможным. С этих позиций наиболее перспективными представляются технологии, позволяющие непосредственно влиять именно на популяцию опухолевых стволовых клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Glioblastoma multiforme</kwd><kwd>carcinogenesis</kwd><kwd>neural stem cells</kwd><kwd>hematopoietic stem cells</kwd><kwd>cancer stem cells</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мультиформная глиобластома</kwd><kwd>канцерогенез</kwd><kwd>нейральные стволовые клетки</kwd><kwd>гемопоэтиче-ские стволовые клетки</kwd><kwd>раковые стволовые клетки</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Баклаушев В.П., Гриненко Н.Ф., Савченко Е.А. и др. Нейральные предшественники и гемопоэтические стволовые клетки подавляют рост низкодифференцированной глиомы. Клеточные технологии в биологии и медицине 2011; 4: 183-90.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Walzlein J.H., Synowitz B., Engels В. et al. The antitumorigenic response of neural precursors depends on subventricular proliferation and age. Stem Cells 2008; 26: 2945-54.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Берсенев А.В. Применение модифицированных нейральных стволовых клеток приводит к эрадикации метастатической нейро-бластомы в эксперименте. Клеточная трансплантология и тканевая инженерия 2007; 2(1): 21.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Altman J. Are new neurons formed in the brains of adult mammals? Science 1962; 135(3509): 1127-8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Викторов И.В. Стволовые клетки мозга млекопитающих: биология стволовых клеток in vivo и in vitro. Известия РАН. Серия биологическая 2001; 6: 646-55.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Weissman L.L. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000; 287(5457): 1442-6.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255(5052): 1707-10.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Eriksson P.S., Perfilieva E., Bjork-Eriksson T. et al. Neurogenesis in the adult human hippocampus. Nature Medicine 1998; 4(11): 1313-7.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Doetsch F., Garcia-Verdugo J.M., Alvarez-Buylla A. Regeneration of a germinal layer in the adult mammalian brain. PNAS USA 1999; 96(20): 11619-24.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Doetsch F., Caille I., Lim D.A.et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain.Cell 1999; 97(6): 703-16.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kempermann G., Chesler E.J., Lu L. et al. Natural variation and genetic covariance in adult hippocampal neurogenesis. PNAS USA 2006; 103(3): 780-85.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Soltanian S., Matin M.M. Cancer stem cells and cancer therapy.Tumour Biology 2011; 32(3): 425-40.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Andreu-Agullo C., Maurin T., Thompson C. B.et al. Ars2 maintains neural stem-cell identity through direct transcriptional activation of Sox2. Nature 2012; 481(7380): 195-8.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kirshenbaum B., Doetsch F., Lois C.et al. Adult subventricular zone neuronal precursors continue to proliferate and migrate in the absence of the olfactory bulb. J. Neuroscience 1999; 19(6): 2171-80.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bass A.J., Wang T.C. An inflammatory situation: SOX2 and STAT3 cooperate in squamous cell carcinoma initiation. Cell Stem Cell 2013; 12(3): 266-8.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sher C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and development 1999; 13(12): 1501-12.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Binda E.,Visioli A., Reynolds B. et al. Heterogeneity of cancer-initiating cells within glioblastoma. Frontiers in bioscience (Scholar Edition) 2012; 4: 1235-48.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gage F.H. Mammalian neural stem cells. Science 2000; 287(5457): 1433-8.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Huang Z., Cheng L., Gurianova O.A. et al. Cancer stem cells in glioblastoma molecular signaling and therapeutic targeting. Protein and cell 2010; 1(7): 638-55.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Annovazzi L., Mellai M., Caldera V. et al. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer genomics and Proteomics 2011; 8(3): 139-47.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Omari K.M., Dorovini-Zis К. CD40 expressed by human brain endothelial cells regulates CD34+ T cell adhesion to endothelium. J. Neuroimmunol 2003; 134(1-2): 166-78.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Wang Y., Yang J., Zheng H. et al. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytesglioma in a murine model. Cancer Cell 2009; 15(6): 514-26.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zheng H, Ying H, Yan H, Kimmelman A.C.et al. P53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455(7216): 1129-33.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Holland E.C., Celestino J., Dai C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature genetics 2000; 25(1): 55-7.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Spits C., Mateizel I., Geens M. et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nature biotechnology 2008; 26(12): 1361-63.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sareen D., McMillan E., Ebert A.D.et al. Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoSone 2009; 4(10): e7630.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kuroda T., Yasuda S., Sato Y. Tumorigenicity studies for human pluripotent stem cell-derived products. Biological and pharmaceutical bulletin 2013; 36(2): 189-92.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Vredenburgh J.J., Desjardins A., Reardon D.A. et al. Experience with irinotecan for the treatment of malignant glioma. Neuro-oncology 2009; 11(1): 80-91.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Брюховецкий А.С. Клеточные технологии в нейроонкологии: циторегуляторная терапия глиальных опухолей головного мозга. М.: Издательская группа РОНЦ; 2011.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Vescovi A.L., Galli R., Reynolds B.A. Brain tumor stem cells. Nature review. Cancer 2006; 6: 425-36.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Piccirillo S.G., Binda E., Fiocco R.et al. Brain cancer stem cells. J. Mol. Med. (Berlin, Germany) 2009; 87(11): 1087-95.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Chen R., Nishimura M.C., Bumbaca S.M. et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17(4): 362-75.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Barrett L.E., Granot Z., Coker C. et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012; 21(1): 11-24.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Dahlrot R.H., Hermansen S.K., Hansen S. et al. What is the clinical value of cancer stem cell markers in gliomas? International journal of clinical and experimental pathology 2013; 6(3): 334-48.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Jin X., Jin X., Jung J.E. et al. Cell surface Nestin is a biomarker for glioma stem cells. Biochemical and biophysical research communications 2013; 433(4): 496-501.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Коржевский Д.Э., Петрова Е.С., Кирик О.В. и др. Нейральные маркеры, используемые при изучении дифференцировки стволовых клеток. Клеточная трансплантология и тканевая инженерия 2010; 5(3): 57-63.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Liu J., Albrecht A.M., Ni X. et al. Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways. Curr. Mol. Med. 2013; 13(3): 352-7.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Aboody K.S., Broun A., Rainbov N.G. et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. PNAS USA 2000; 97(23): 12846-51.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Glass R., Synowitz M., Kronenberg G.et al. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J. Neuroscience 2005; 25(10): 2637-46.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Robin A. M., Zhang Z. G., Wang L. et al. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J. Cerebr. Blood Flow Metabol. 2006; 26(1): 125-34.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Mohle R., Bautz F., Rafii S. et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates trans endothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91(12): 4523-30.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Yin D., Zhang Z., Gao S.et al. The role of chemokine receptor CXCR4 and its ligand CXCL12 in the process of proliferation and migration of oral squamous cell carcinoma. West China J. Stomatol. 2013; 31(1): 8-12.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Greenbaum A., Hsu Y.M., Day R.B. et al. CXCL12 in early mesenchymal progenitors is required for hematopoietic stem-cell maintenance. Nature 2013; 495(7440): 227-30.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Imitola J., Comabella M., Chandraker A.K.et al. Neural stem/ progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Amer. J. Pathol. 2004; 164(5): 1615-25.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Sahin A.O., Buitenhuis M. Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells. Cell Adhes. Migrat. 2012; 6(1): 39-48.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Yip S., Aboody K.S., Burns M. et al. Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer 2003; 9(3): 189-204.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Пальцев М.А., Иванов А.А., Северин С.Е. Межклеточное взаимодействие. М.: Медицина 2003.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Ермаков А.В., Конькова М.С., Костюк С.В. и др. Развитие эффекта свидетеля в мезенхимальных стволовых клетках человека после воздействия рентгеновского излучения в адаптирующей дозе. Радиационная биология и радиоэкология 2010; 50 (1): 42-51.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Buckner J.C., Brown P.D., O'Neill B.P. et al. Central nervous system tumors. Mayo Clinic proceedings. Mayo Clinic 2007; 82(10): 1271-86.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Bajeto A., Barbieri F., Dorcaratto A. et al. Expression of CXC chemokine receptor 1-5and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cells proliferation and migration. Neurochemistry International 2006; 49(5): 423-32.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Mirisola V., Zuccarino A., Bachmeier B.E. et al. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. European J. Cancer 2009; (14): 2579-87.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Zhou Y., Larsen P.Y., Hao C.et al.CXCR4 is a major chemokine receptor onglioma cells and mediates their survival. J. Biol. Chem. 2002; 227 (51): 49481-7.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Voermans C., Anthoni E.C., Mul E. et al. SDF-1 induced actin polymerization and migration in human hematopoietic progenitor cells. Exper. Hematol. 2001; 29(12): 1456-64.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Великанов Г.А., Леванов В.Ю., Белова Л.П. и др. Регулируемое русло для диффузии между вакуолями соседних клеток: ва-куолярный симпласт. Успехи современной биологии 2012; 132(1): 36-50.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Tang W., Duan J., Zhang J.G. et al. Subtyping glioblastoma by combining miRNA and mRNA expression data using compressed sensing-based approach. EURASIP J. Bioinform. Syst. Biol.; 2013(1): 2.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Marsden C.G., Wright M.J., Pochampally R. et al. Breast tumor-initiatingcells isolated from patient core biopsies for study of hormone action. Method. Mol. Biol. 2009; 590: 363-75.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Manoranjan B., Venugopal C., McFarlane N.et al. Medullo-blastoma stem cells: where development and cancer cross pathways. Pediatric research 2012; 71(4 Pt 2): 516-22.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Ding L., Morrison S.J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 2013; 495(7440): 231-5.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Ratajczak M.Z., Kim C., Ratajczak J. et al. Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/ progenitor cells. Advanc. Experimen. Med. Biol. 2013; 735: 219-32.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Dougherty J.D., Fomchenko E.I., Akuffo A.A. et al. Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Research 2012; 72(18): 4856-68.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Piccirillo S.G., Binda E., Fiocco R. et al. Brain cancer stem cells. J. Mol. Med. (Berlin, Germany) 2009; 87(11): 1087-95.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Tang W., Huang Y., Chen L. et al. Small intestinal tubular adenoma in a pediatric patient with Turner syndrome. World J. Gastroenterol. 2013; 19(13): 2122-25.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Anbalagan M., Ali A., Jones R.K. et al. Peptidomimetic Src/ pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol. Cancer Therap. 2012; 11(9): 1936-47.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Fukuda S., Broxmeyer H.E., Pelus L.M. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha (CXCL12)/CXCR4 axis. Blood 2005; 105(8): 3117-26.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>He J., Liu Y., Zhu T.S. et al. Glycoproteomic analysis of glioblastoma stem cell differentiation. J. Proteome Research 2011; 10(1): 330—8.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Ceyhan G.O., Giese N.A., Erkan M. et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann. Surgery 2006; 244(2): 274—81.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Ceyhan G.O., Bergmann F., Kadihasanoglu M. et al. Theneurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis. Gut. 2007; 56(4): 534—44.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Strizzi L., Bianco C, Raafat A. et al. Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J. Cell Sci. 2005; 118(Pt 20): 4633—43.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Ohira K., Homma K.J., Hirai H. et al. TrkB-T1 regulates the RhoA signaling and actin cytoskeleton in glioma cells. Biochem. Biophys. Res. Comm. 2006; 342(3): 867—74.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Bajetto A., Porcile C., Pattarozzi A. et al. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility. J. Biol. Regul. Homeost. Agents. 2013; 27(1): 143—54.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Adini A., Adini I., Ghosh K. et al. The stemcell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action. Angiogenesis 2013; 16(2): 405—16.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Arien-Zakay H., Lecht S., Nagler A. et al. Neuroprotection by human umbilical cord blood-derived progenitors in ischemic brain injuries. Arch. Italien. Biol. 2011; 149(2): 233—45.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Varner J.A. Stem cells and neurogenesis in tumors. Progress in experimental tumor research 2007; 39: 122—9.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Halvorson K.G., Sevcik M.A., Ghilardi J.R. et al. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer. J. Pain Sympt. Manag. 2008; 36(3): 289—303.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Jimenez-Andrade J.M., Martin C.D., Koewler N.J. et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 2007; 133(1—3): 183—96.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Basile J.R., Castilho R.M., Williams V.P. et al. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. PNAS USA 2006; 103(24): 9017—22.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Nakamura K., Yashiro M., Matsuoka T. et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterol. 2006; 131(5): 1530—41.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Yazdani U., Terman J.R. The semaphorins. Genome biology 2006; 7(3): 211.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Ellis L.M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Seminaries in oncology 2006; 33: S1—7.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Ellis L.M. The role of neuropilins in cancer. Mol. Canc. Ther. 2006; 5(5): 1099—107.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Spicer J.A. New small-molecule inhibitors of mitogen-activated protein kinase. Expert Opin.n Drug Discov. 2008; 3(7): 801—17.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Zhou H., Binmadi N.O., Yang Y.H. et al. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 2012; 15(3): 391—407.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Sakurai A., Gavard J., Annas-Linhares Y. et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol. Cell. Biol. 2010; 30(12): 3086—98.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Garmy-Susini B., Varner J.A. Circulating endothelial progenitor cells. British J. Cancer 2005; 93(8): 855—8.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Manoranjan B., Venugopal C., McFarlane N. et al. Medulloblastoma stem cells: where development and cancer cross pathways. Pediat. Res. 2012; 71(4 Pt 2): 516—22.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Wang X., Venugopal C., Manoranjan B. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012; 31(2): 187—99.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Martinez-Ferre A., Navarro-Garberi M., Bueno C. et al. Wnt Signal Specifies the Intrathalamic Limit and Its Organizer Properties by Regulating Shh Induction in the Alar Plate. J. Neurosci. 2013; 33(9): 3967—80.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Hu J., Huang X., Hong X. et al. Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Canc. Cell Inter. 2013; 13(1): 25.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Устьянцева И.М. Апоптоз и воспалительный ответ. Политравма 2007; 1:74—80.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Leong S.Y., Faux C.H., Turbic A.et al. The Rho kinase pathway regulates mouse adult neural precursor cell migration. Stem cells 2011; 29(2): 332—43.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Hirschmann -Jax C., Foster A.E., Wulf G.G. et al. A distinct «side population» of cells with high drug efflux capacity in human tumor cells. PNAS USA 2004; 101: 14228—33.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Hegi M.E., Diserens A.C., Gorlia T. et al. MGMT gene silencing and benefit from temozolamide in glioblastoma. New Eng. J. Med. 2005; 352: 997—1003.</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Bao S., Wu Q., McLendon R.E. et al. Glioma stem cell promotes radioresistance by preferential activation of DNA damage response. Nature 2006; 444: 756—60.</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Bach P., Abel T., Hoffmann C. et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Canc. Res. 2013; 73(2): 865—74.</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Manning G., Whyte D.B., Martinez R. et al. The protein kinase complement of the human genome. Science 2002; 298(5600): 1912—34.</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Stricker S.H., Feber A., Engstrom P.G. et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Gen. Develop. 2013; 27(6): 654—69.</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Xie L.Q., Sun H.P., Wang T. et al. Reprogramming of adult human neural stem cells into induced pluripotent stem cells. Chinese Med. J.2013; 126(6): 1138—43.</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Bo Y., Guo G., Yao W. miRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. J. Neurooncol. 2013; 112(1): 27—37.</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Prior H.M., Walter M.A. SOX genes: architects of development. Mol. Med. 1996; 2(4): 405—12.</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Bazzoli E., Pulvirenti T., Oberstadt M.C. et al. MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 2012; 11(6): 836—44.</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Murphy A.M., Rabkin S.D. Current status of gene therapy for brain tumors. Transl. Res. 2013; 161(4): 339—54.</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Snapyan M., Lemasson M., Brill M.S. et al. Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brain-derived neurotrophic factor signaling. J. Neurosci. 2009; 29(13): 4172—88.</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Teramoto T., Qiu J., Plumier J. C. et al. EGF amplifies the replacement of parvalbumin-expressing striatal interneurons after ischemia. J. Clin. Invest. 2003; 111: 1125—32.</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation>Ben-Hur T., Ben-Menachem O., Furer V. et al. Effects of proin flammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol. Cell. Neurosci. 2003; 24(3): 623—31.</mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation>Kobayashi N., Navarro-Alvares N., Soto-Gutieres A. et al. Cancer stem cell research; current situation and problem. Cell Transpl. 2008; 17(1-2): 19—25.</mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation>Shi N., Pardridge W.M. Noninvasive gene targeting to the brain. PNAS USA 2000; 97(13): 7567—72.</mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation>Navarro-Alvarez N., Kondo E., Kawamoto H.et al. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transpl. 2010; 19(6): 865—77.</mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation>Cheng L., Alexander R., Zhang S. et al. The clinical and therapeutic implications of cancer stem cell biology. Expert Rev. Anticanc.Ther. 2011; 11(7): 1131—43.</mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation>Tabatabai G., Bahr O., Mohle R. et al. Lessons from the bone marrow: how malignant glioma cells attract adult hematopoietic progenitor cells. Brain 2005; 128(9): 2200—11.</mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation>Брюховецкий А.С., Чехонин В.П., Семенова А.В. и др. Противоопухолевое средство на основе иммунолипосомальной биологической конструкции, способ его получения и векторной доставки в центральную нервную систему при опухолевом процессе. Патент РФ на изобретение № 2336901 от 27.10.2008.</mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation>Khurana B., Goyal A.K., Budhiraja A. et al. Lipoplexes versus nanoparticles: pDNA/siRNA delivery. Drug delivery 2013; 20(2): 57—64.</mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation>Duman B.B., Sahin B., Acikalin A. et al. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J. B.U.ON 2013; 18(1): 44—50.</mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation>Ortensi B., Setti M., Osti D. et al. Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res. Ther. 2013; 4(1): 18.</mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation>Peled A., Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 2013; 3(1): 34—9.</mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation>Lin C.Y., Wang L., Than K. et al. Cancer stem cell markers: what is their diagnostic value? Expert Opin. Med. Diagnost. 2010; 4(6): 473—81.</mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation>Tarnowski M., Liu R., Wysoczynski M.et al. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34( + ) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Euro. J. Haematol. 2010; 85(6): 472—83.</mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation>Tang Y., Shah K., MesserliS. M. et al. In vivo tracking of neural progenitor cell migration to glioblastomas. Human gene therapy 2003; 14(13): 1247—54.</mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation>Foubert P., Varner J.A. Integrin's in tumor angiogenesis and lymphangiogenesis. Meth. Mol. Biol. 2012; 757: 471—86.</mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation>Zalatimo O., Zoccoli C.M. Patel A. et al. Impact of genetic targets on primary brain tumor therapy: what's ready for prime time? Advanc. Inexper. Med. Biol. 2013; 779: 267—89.</mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation>Holland E.C. Gliomagenesis: genetic alterations and mouse models. Genetics 2001; 2: 120—9.</mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation>Reya T., Morrison S.J., Clarke M.F.et al. Stem cell, cancer, and cancer stem cell. Nature 2001; 423: 409—14.</mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation>Charles N.A., Holland E.C., Gilbertson R. et al. The brain tumor microenvironment. Glia 2012; 60(3): 502—14.</mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation>Dvorak P., Dvorakova D., Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Letters 2006; 580(12): 2869—74.</mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation>Jiang W., Peng J., Zhang Y. et al. The implications of cancer stem cells for cancer therapy. Inter. J. Mol. Sci. 2012; 13(12): 16636—57.</mixed-citation></ref></ref-list></back></article>
